Related Experiment Videos
ErbB receptor tyrosine kinase inhibitors as therapeutic agents
Neil G Anderson1, Tawhid Ahmad
1Division of Cancer Studies, School of Medicine, University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom. anderson@man.ac.uk
Abstract:
The ErbB family of receptor tyrosine kinases comprise four members: EGFR, ErbB2, ErbB3 and ErbB4. All are essential for normal development and participate in the functioning of normal cells. ErbB receptors, particularly EGFR and ErbB2 are commonly deregulated in certain prevalent forms of human cancer. Recently a number of small molecule inhibitors of the tyrosine kinase activity of these receptors have been developed. Some of these agents, known as TKIs, are progressing through clinical trials in patients with aberrant ErbB receptor expression in their tumors. This article provides a brief overview on the structure and biology of ErbB receptors and their ligands before discussing in detail the development and current status of ErbB receptor TKIs. These agents are shown to inhibit multiple features of cancer cells including proliferation, survival, invasion and angiogenesis. It is clear from recent studies that not all cancer cells that overexpress ErbB receptors will be sensitive to TKIs. Potential explanations for resistance to these molecules are reviewed. Finally the prospect of using TKIs in combination with existing chemotherapeutic agents is discussed.
Insights
Small molecule inhibitors targeting ErbB receptor tyrosine kinases (TKIs) show promise in treating cancers with aberrant ErbB expression. However, resistance mechanisms necessitate further research into combination therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The ErbB receptor family (EGFR, ErbB2, ErbB3, ErbB4) is crucial for normal development and cell function.
- Deregulated ErbB receptors, especially EGFR and ErbB2, are implicated in various human cancers.
- Small molecule inhibitors targeting ErbB receptor tyrosine kinase activity (TKIs) have been developed.
Purpose of the Study:
- To provide an overview of ErbB receptor structure, biology, and ligands.
- To discuss the development and clinical status of ErbB receptor TKIs.
- To review potential resistance mechanisms and combination therapy prospects.
Main Methods:
- Literature review of ErbB receptor biology and TKI development.
- Analysis of TKI efficacy against cancer cell proliferation, survival, invasion, and angiogenesis.
- Exploration of resistance mechanisms to TKIs.
- Discussion of combination strategies with chemotherapeutic agents.
Main Results:
- ErbB receptor TKIs inhibit key cancer cell features like proliferation and angiogenesis.
- Not all cancer cells overexpressing ErbB receptors are sensitive to TKIs, indicating resistance.
- Resistance mechanisms to TKIs require further investigation.
Conclusions:
- ErbB receptor TKIs represent a significant advancement in cancer therapy for specific patient populations.
- Understanding and overcoming TKI resistance is critical for improving treatment outcomes.
- Combination therapies involving TKIs and chemotherapy may offer enhanced efficacy.